BLU News and Press, BELLUS Health Inc. From 02/23/22

- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to request an End-of-Phase 2 meeting with the Food and Drug Administrat...

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 25,000,000 common s...

Common Shares Priced at US$8.00 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and N...

BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022. T...

On a weak day for the overall equity market, COVID vaccine makers presented a bright spot on Monday. New data showing potential against the Omicron variant gave strength to Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:N...

BELLUS Health (NASDAQ:BLU) trades 2.2% down after hours on filing a prelim prospectus supplement for a proposed public offering of its shares worth $175M; underwriters to be granted 30-day option to purchase up to an additional 15% of the shares. The supplement was filed with e...

Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arena Pharmaceuticals (NASDAQ: ARNA ) stock is flying higher on Monday thanks to a huge deal with Pfizer (NYSE: PFE ). Source: Manuel Esteban / Shutterstock.com Pfizer signed a definitive agreement that ...

BELLUS Health (TSX:BLU) (NASDAQ:BLU) shares soared 60% on Monday after the company announced positive results from its trial for the treatment of chronic cough. What happened? Shares Bellus exploded back towards pre-pandemic levels after the release of its trial resu...

Shares of Bellus Health (NASDAQ: BLU) , a clinical-stage biotechnology company, are soaring in response to positive clinical-trial data. Investors excited about the company's lead candidate BLU-5937 drove the stock 58.4% higher as of 10:30 a.m. ET on Monday. Bellus Health's lead...